United Therapeutics Corporation : Warner Chilcott, Dynavax Technologies, Isis Pharma, United Therapeutics, and Pharmacyclics Under StockCall's Microscope
03/13/2013| 07:05am US/Eastern
Recommend:
LONDON, March 13, 2013 /PRNewswire/ --
The healthcare industry is adapting to the changing market dynamics. One of the
biggest trends in the industry has been President Obama's comprehensive healthcare reform,
Affordable Care Act (ACA). While ACA poses significant challenges to drug manufacturers
such as Warner Chilcott Plc (NASDAQ: WCRX), Dynavax Technologies Corp. (NASDAQ: DVAX),
ISIS Pharmaceuticals Inc. (NASDAQ: ISIS), United Therapeutics Corp. (NASDAQ: UTHR), and
Pharmacyclics Inc. (NASDAQ: PCYC), another challenge for drug manufacturers has been
increasing competition from generics following the expiration of patents on several
blockbuster drugs in recent years. On Tuesday, healthcare stocks ended on a mixed note as
the broad market struggled after a week-long rally. StockCall has released full
comprehensive research on WCRX, DVAX, ISIS, UTHR, and PCYC and these free technical
analyses can be downloaded by signing up at
http://www.stockcall.com/technicalanalysis
Shares of Warner Chilcott Plc fell sharply in Tuesday's trading session. The stock
closed 1.10% lower at $13.46 on volume of 3.58 million. Despite the sharp decline
yesterday, the stock is still up more than 1% in the last three sessions. Even as the
healthcare industry faces challenges, Warner Chilcott's shares have performed well this
year, gaining nearly 12%, compared to a gain of nearly 9% for the S&P 500. The stock is
currently facing stiff resistance at around $13.75. Free technical analysis on WCRX
available by signing up at
http://www.StockCall.com/WCRX031313.pdf
Shares of Dynavax Technologies Corporation saw a huge rally in Tuesday's trading
session even as the broad market struggled. The stock ended the day 9.23% higher at $2.13
on volume of 3.29 million yesterday. In spite of Tuesday's rally, Dynavax's shares have
fallen more than 25% this year. The stock broke through $2 resistance level yesterday,
which is a bullish signal. The upbeat trend is further confirmed by the stock's MACD
chart. Register today and access the free research on DVAX at
http://www.StockCall.com/DVAX031313.pdf
Shares of ISIS Pharmaceuticals Inc. rose sharply in Tuesday's session. The stock
closed 1.36% higher at $17.94 on volume of 1.21 million. ISIS Pharmaceuticals shares have
seen a series of highs in the last few trading sessions, which is a strong bullish signal.
The stock has also broken through $15 resistance level. The optimistic trend is further
confirmed by recent volume activity and the stock's MACD chart. The free report on ISIS
can be downloaded by signing up now at
http://www.StockCall.com/ISIS031313.pdf
Shares of United Therapeutics Corp. posted modest gains in Tuesday's trading session.
The stock closed 0.64% higher at $62.49 on above average volume of 967,367. Yesterday,
United Therapeutics' shares reached a 52-week high of $62.61. The stock has had an
excellent run in 2013, gaining nearly 17%. The drug maker's shares have seen a series of
highs in the last one month, which is a strong bullish signal. The positive trend is
further confirmed by recent volume activity. Free report on UTHR can be accessed by
registering at
http://www.StockCall.com/UTHR031313.pdf
Shares of Pharmacyclics Inc. fell sharply in Tuesday's trading session. The stock
closed 1.31% lower at $90.96 on above average volume of 897,740. Pharmacyclics' shares are
currently trading close to their 52-week high of $95.85. The stock has fallen more than
3.70% in the last three trading sessions. Register with StockCall and download the
research on PCYC for free at
http://www.StockCall.com/PCYC031313.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to talk
to our financial analyst at
http://www.stockcall.com
SOURCE StockCall.com
Recommend :
